- Home
- VRPX vs ALLR Comparison
VRPX vs ALLR Comparison
Compare VRPX & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRPX
- ALLR
- Stock Information
- Founded
- VRPX 2016
- ALLR 2004
- Country
- VRPX United States
- ALLR United States
- Employees
- VRPX N/A
- ALLR N/A
- Industry
- VRPX Medicinal Chemicals and Botanical Products
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- VRPX Health Care
- ALLR Health Care
- Exchange
- VRPX Nasdaq
- ALLR Nasdaq
- Market Cap
- VRPX 3.3M
- ALLR 3.2M
- IPO Year
- VRPX 2021
- ALLR N/A
- Fundamental
- Price
- VRPX $0.64
- ALLR $1.76
- Analyst Decision
- VRPX Strong Buy
- ALLR
- Analyst Count
- VRPX 1
- ALLR 0
- Target Price
- VRPX $3.00
- ALLR N/A
- AVG Volume (30 Days)
- VRPX 52.5K
- ALLR 1.0M
- Earning Date
- VRPX 11-13-2024
- ALLR 11-12-2024
- Dividend Yield
- VRPX N/A
- ALLR N/A
- EPS Growth
- VRPX N/A
- ALLR N/A
- EPS
- VRPX N/A
- ALLR N/A
- Revenue
- VRPX N/A
- ALLR N/A
- Revenue This Year
- VRPX N/A
- ALLR N/A
- Revenue Next Year
- VRPX N/A
- ALLR N/A
- P/E Ratio
- VRPX N/A
- ALLR N/A
- Revenue Growth
- VRPX N/A
- ALLR N/A
- 52 Week Low
- VRPX $0.46
- ALLR $1.63
- 52 Week High
- VRPX $9.00
- ALLR $666.00
- Technical
- Relative Strength Index (RSI)
- VRPX 34.79
- ALLR 26.80
- Support Level
- VRPX $0.63
- ALLR $1.63
- Resistance Level
- VRPX $0.70
- ALLR $2.40
- Average True Range (ATR)
- VRPX 0.05
- ALLR 0.36
- MACD
- VRPX 0.00
- ALLR 0.01
- Stochastic Oscillator
- VRPX 6.21
- ALLR 6.25
About VRPX Virpax Pharmaceuticals Inc.
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.